Xeris Biopharma Holdings (XERS)
Xeris Biopharma Holdings on one page: short interest, daily short volume, fails to deliver, planned sales, large holders, 13F holders, financials, earnings dates and insider trades. Listed on Nasdaq, classified by the SEC as pharmaceutical preparations.
8.0M
Short interest
settlement 2026-10-15
3.3
Days to cover
+1.5 days vs prior
30.7%
Short share of volume
2026-11-02
209,157
Fails to deliver
settlement 2026-09-30
Thu 5 Nov
Next earnings
estimated date
-$949K
Insider flow, 90 days
0 buys, 8 sells
As of 2026-11-02.
Short interest
FINRA, twice a month. The newest 48 settlements in the table, 48 in the chart. JSONAs of 15 October 2026, short interest in XERS is 8,027,654 shares, down 31,323 shares over the last month. Over the last 48 readings it ranged from 7,202,379 shares (30 September 2026) to 19,965,518 shares (30 June 2025). The latest reading sits at the bottom of that range. At the reported average volume of 2.5M shares a day that is 3.3 days to cover.
Embed this chart.The embed keeps its attribution line.
<iframe src="https://xoomar.com/embed/stocks/xers" width="100%" height="440" style="border:0;max-width:100%" loading="lazy" title="XOOMAR chart"></iframe>
| Settlement | Shares short | Change | Avg daily volume | Days to cover |
|---|---|---|---|---|
| 2026-10-15 | 8,027,654 | +11.5% | 2,463,188 | 3.26 |
| 2026-09-30 | 7,202,379 | -10.6% | 4,146,096 | 1.74 |
| 2026-09-15 | 8,058,977 | +0.2% | 1,667,316 | 4.83 |
| 2026-08-31 | 8,041,258 | -7.9% | 1,471,149 | 5.47 |
| 2026-08-14 | 8,728,856 | -5.3% | 1,965,890 | 4.44 |
| 2026-07-31 | 9,221,405 | -8.5% | 1,366,174 | 6.75 |
| 2026-07-15 | 10,078,469 | -21.0% | 2,299,463 | 4.38 |
| 2026-06-30 | 12,760,034 | -0.4% | 2,343,847 | 5.44 |
| 2026-06-15 | 12,810,046 | +2.4% | 1,746,604 | 7.33 |
| 2026-05-29 | 12,514,253 | +1.2% | 1,328,898 | 9.42 |
| 2026-05-15 | 12,364,664 | -22.2% | 2,131,991 | 5.80 |
| 2026-04-30 | 15,894,656 | +1.0% | 1,253,626 | 12.68 |
| 2026-04-15 | 15,738,746 | -4.1% | 1,429,569 | 11.01 |
| 2026-03-31 | 16,412,903 | +1.2% | 1,835,043 | 8.94 |
| 2026-03-13 | 16,223,073 | -4.7% | 2,396,368 | 6.77 |
| 2026-02-27 | 17,015,319 | -2.1% | 2,277,410 | 7.47 |
| 2026-02-13 | 17,385,964 | +2.3% | 1,252,005 | 13.89 |
| 2026-01-30 | 16,996,095 | +0.7% | 1,476,763 | 11.51 |
| 2026-01-15 | 16,883,379 | +2.2% | 2,796,279 | 6.04 |
| 2025-12-31 | 16,522,754 | +7.0% | 2,132,434 | 7.75 |
| 2025-12-15 | 15,434,811 | -3.4% | 2,228,593 | 6.93 |
| 2025-11-28 | 15,974,039 | +1.4% | 1,777,937 | 8.98 |
| 2025-11-14 | 15,746,194 | -10.7% | 3,924,309 | 4.01 |
| 2025-10-31 | 17,626,897 | -1.3% | 2,048,398 | 8.61 |
| 2025-10-15 | 17,850,615 | +2.4% | 2,321,770 | 7.69 |
| 2025-09-30 | 17,441,089 | +7.4% | 2,328,723 | 7.49 |
| 2025-09-15 | 16,240,329 | +10.4% | 1,623,682 | 10.00 |
| 2025-08-29 | 14,713,733 | +10.2% | 2,165,002 | 6.80 |
| 2025-08-15 | 13,346,477 | -26.8% | 4,590,576 | 2.91 |
| 2025-07-31 | 18,222,832 | -6.8% | 1,449,683 | 12.57 |
| 2025-07-15 | 19,554,170 | -2.1% | 2,120,367 | 9.22 |
| 2025-06-30 | 19,965,518 | +11.3% | 2,301,320 | 8.68 |
| 2025-06-13 | 17,940,320 | +1.9% | 2,344,449 | 7.65 |
| 2025-05-30 | 17,600,227 | -1.1% | 1,767,753 | 9.96 |
| 2025-05-15 | 17,803,095 | +3.4% | 2,417,734 | 7.36 |
| 2025-04-30 | 17,225,333 | -9.6% | 2,100,143 | 8.20 |
| 2025-04-15 | 19,050,282 | +11.8% | 3,538,342 | 5.38 |
| 2025-03-31 | 17,038,478 | +52.0% | 4,334,320 | 3.93 |
| 2025-03-14 | 11,209,763 | +5.4% | 4,357,303 | 2.57 |
| 2025-02-28 | 10,633,524 | +3.6% | 2,173,277 | 4.89 |
| 2025-02-14 | 10,265,230 | -2.1% | 1,397,574 | 7.35 |
| 2025-01-31 | 10,485,254 | +1.2% | 1,389,398 | 7.55 |
| 2025-01-15 | 10,361,048 | +1.7% | 1,587,806 | 6.53 |
| 2024-12-31 | 10,188,099 | +7.0% | 1,194,752 | 8.53 |
| 2024-12-13 | 9,517,445 | -3.9% | 2,069,512 | 4.60 |
| 2024-11-29 | 9,908,169 | -2.4% | 1,201,740 | 8.24 |
| 2024-11-15 | 10,146,898 | -10.8% | 2,418,759 | 4.20 |
| 2024-10-31 | 11,373,240 | -1.7% | 1,219,457 | 9.33 |
Daily short volume
FINRA Reg SHO, the last 30 sessions. JSONAs of 2 November 2026, the short share of XERS volume is 30.7%, down 8.7 points over the last five sessions. Over the last 30 readings it ranged from 22.9% (30 October 2026) to 53.6% (16 October 2026). The latest reading is 5.4 points below the 30-session average of 36.1%, on 838K shares reported.
| Date | Short volume | Total volume | Short share | Exempt |
|---|---|---|---|---|
| 2026-11-02 | 257K | 838K | 30.7% | 1,394 |
| 2026-10-30 | 130K | 570K | 22.9% | 4,118 |
| 2026-10-29 | 212K | 734K | 28.9% | 1,900 |
| 2026-10-28 | 151K | 526K | 28.6% | 332 |
| 2026-10-27 | 283K | 727K | 38.9% | 982 |
| 2026-10-26 | 305K | 775K | 39.4% | 602 |
| 2026-10-23 | 310K | 816K | 37.9% | 3,649 |
| 2026-10-22 | 215K | 664K | 32.5% | 700 |
| 2026-10-21 | 191K | 754K | 25.3% | 301 |
| 2026-10-20 | 337K | 1.2M | 29.2% | 2,453 |
| 2026-10-19 | 687K | 2.1M | 32.4% | 10,049 |
| 2026-10-16 | 422K | 786K | 53.6% | 1,167 |
| 2026-10-15 | 237K | 591K | 40.1% | 5,645 |
| 2026-10-14 | 230K | 673K | 34.2% | 791 |
| 2026-10-13 | 196K | 622K | 31.5% | 4,960 |
| 2026-10-12 | 152K | 535K | 28.4% | 1,945 |
| 2026-10-09 | 423K | 972K | 43.6% | 15,187 |
| 2026-10-08 | 246K | 750K | 32.8% | 4,128 |
| 2026-10-07 | 193K | 645K | 29.9% | 568 |
| 2026-10-06 | 318K | 878K | 36.2% | 14,118 |
| 2026-10-05 | 756K | 1.8M | 41.1% | 5,822 |
| 2026-10-02 | 248K | 505K | 49.2% | 8,449 |
| 2026-10-01 | 434K | 944K | 46.0% | 5,920 |
| 2026-09-30 | 328K | 866K | 37.8% | 8,594 |
| 2026-09-29 | 3.2M | 7.7M | 41.1% | 16,774 |
| 2026-09-28 | 569K | 1.6M | 36.6% | 15,135 |
| 2026-09-25 | 195K | 623K | 31.3% | 16 |
| 2026-09-24 | 164K | 439K | 37.3% | 229 |
| 2026-09-23 | 456K | 891K | 51.2% | 1,523 |
| 2026-09-22 | 221K | 633K | 35.0% | 355 |
Fails to deliver
SEC, the last 30 settlement dates with a fail. JSONAs of 30 September 2026, the fails-to-deliver balance in XERS is 209,157 shares, up 194,978 shares over the last settlement date. Over the last 30 readings it ranged from 1 share (12 August 2026) to 209,157 shares (30 September 2026). The latest reading sits at the top of that range.
| Settlement | Shares failed | Price | Value |
|---|---|---|---|
| 2026-09-30 | 209,157 | $9.98 | $2.1M |
| 2026-09-29 | 14,179 | $9.83 | $139K |
| 2026-09-23 | 106 | $8.73 | $925 |
| 2026-09-08 | 21 | $8.53 | $179 |
| 2026-09-02 | 24 | $8.43 | $202 |
| 2026-08-18 | 679 | $8.52 | $6K |
| 2026-08-13 | 1 | $8.49 | $8 |
| 2026-08-12 | 1 | $8.39 | $8 |
| 2026-08-04 | 83 | $8.13 | $675 |
| 2026-07-20 | 3,200 | $8.80 | $28K |
| 2026-07-14 | 50,000 | $8.16 | $408K |
| 2026-06-29 | 5,095 | $7.69 | $39K |
| 2026-06-15 | 591 | $6.79 | $4K |
| 2026-06-12 | 1,684 | $6.93 | $12K |
| 2026-06-10 | 14,847 | $6.50 | $97K |
| 2026-05-18 | 2,000 | $6.24 | $12K |
| 2026-04-20 | 17,329 | $6.37 | $110K |
| 2026-04-09 | 1,440 | $5.92 | $9K |
| 2026-03-31 | 18,435 | $5.60 | $103K |
| 2026-03-12 | 3 | $5.73 | $17 |
| 2026-02-23 | 35 | $6.61 | $231 |
| 2026-01-20 | 8,000 | $7.52 | $60K |
| 2025-12-10 | 3,460 | $7.01 | $24K |
| 2025-12-05 | 700 | $6.72 | $5K |
| 2025-12-04 | 350 | $6.73 | $2K |
| 2025-11-19 | 1,963 | $7.08 | $14K |
| 2025-11-17 | 326 | $7.18 | $2K |
| 2025-11-12 | 3,040 | $7.44 | $23K |
| 2025-11-06 | 28,142 | $9.87 | $278K |
| 2025-10-30 | 6,899 | $9.62 | $66K |
Insider trades
SEC Form 4, newest first. JSONInsiders at XERS reported 8 open-market sells worth $949K in the last 90 days and no open-market buys. Latest filing: McCulloch Kevin (See Remarks) on 2026-10-01.
| Date | Insider | Title | Type | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|---|
| 2026-10-01 | McCulloch Kevin | See Remarks | Sell | 15K | $9.41 | $141K | 1.6M |
| 2026-10-01 | Hecht Beth | See Remarks | Sell | 17K | $9.41 | $157K | 1.1M |
| 2026-10-01 | Pieper Steven | See Remarks | Sell | 5K | $9.41 | $47K | 1.4M |
| 2026-09-28 | McCulloch Kevin | See Remarks | Sell | 25K | $10.00 | $250K | 1.6M |
| 2026-09-01 | Pieper Steven | See Remarks | Sell | 5K | $8.50 | $43K | 1.4M |
| 2026-09-01 | McCulloch Kevin | See Remarks | Sell | 15K | $8.49 | $127K | 1.6M |
| 2026-09-01 | Hecht Beth | See Remarks | Sell | 17K | $8.49 | $141K | 1.1M |
| 2026-08-12 | Pieper Steven | See Remarks | Sell | 5K | $8.50 | $43K | 1.4M |
| 2026-08-03 | McCulloch Kevin | See Remarks | Sell | 15K | $8.02 | $120K | 1.7M |
| 2026-08-03 | Hecht Beth | See Remarks | Sell | 17K | $8.01 | $134K | 1.1M |
| 2026-08-01 | Shannon John Patrick Jr | See Remarks | Tax withholding | 37K | $8.08 | $296K | 2.9M |
| 2026-08-01 | McCulloch Kevin | See Remarks | Tax withholding | 22K | $8.08 | $177K | 1.7M |
| 2026-07-07 | Pieper Steven | See Remarks | Sell | 28K | $8.52 | $235K | 1.4M |
| 2026-07-06 | Pieper Steven | See Remarks | Sell | 17K | $8.50 | $148K | 1.4M |
| 2026-07-01 | McCulloch Kevin | See Remarks | Sell | 90K | $8.03 | $723K | 1.7M |
| 2026-07-01 | KREHER NERISSA | Director | Grant | 34K | $0.00 | $0 | 34K |
| 2026-07-01 | Hecht Beth | See Remarks | Sell | 17K | $8.03 | $134K | 1.2M |
| 2026-06-04 | PERSKY MARLA | Director | Grant | 24K | $0.00 | $0 | 151K |
| 2026-06-04 | Kong Garheng | Director | Grant | 24K | $0.00 | $0 | 238K |
| 2026-06-04 | JOHNSON JOHN | Director | Grant | 24K | $0.00 | $0 | 707K |
| 2026-06-04 | JOHNSON JOHN | Director | Sell | 15K | $6.09 | $91K | 683K |
| 2026-06-04 | HALKUFF DAWN | Director | Grant | 24K | $0.00 | $0 | 119K |
| 2026-06-04 | HALKUFF DAWN | Director | Sell | 20K | $6.09 | $122K | 95K |
| 2026-06-04 | Brady James Aloysius | Director | Grant | 24K | $0.00 | $0 | 113K |
| 2026-06-04 | BORMANN-KENNEDY BARBARA-JEAN ANNE | Director | Grant | 24K | $0.00 | $0 | 151K |
| 2026-06-04 | BORMANN-KENNEDY BARBARA-JEAN ANNE | Director | Sell | 16K | $6.09 | $98K | 127K |
| 2026-06-03 | PERSKY MARLA | Director | Sell | 16K | $5.90 | $91K | 127K |
| 2026-06-01 | Hecht Beth | See Remarks | Sell | 17K | $6.06 | $101K | 1.2M |
| 2026-05-01 | Hecht Beth | See Remarks | Sell | 17K | $6.23 | $104K | 1.2M |
| 2026-04-01 | Hecht Beth | See Remarks | Sell | 17K | $5.99 | $100K | 1.2M |
| 2026-03-30 | Brady James Aloysius | Director | Sell | 11K | $5.54 | $60K | 89K |
| 2026-03-12 | McCulloch Kevin | See Remarks | Exercise or conversion | 4 | $3.94 | $16 | 1.8M |
| 2026-03-12 | McCulloch Kevin | See Remarks | Exercise or conversion | 49K | $4.09 | $200K | 1.8M |
| 2026-03-05 | Pieper Steven | See Remarks | Exercise or conversion | 14K | $5.93 | $83K | 1.4M |
| 2026-03-05 | Pieper Steven | See Remarks | Exercise or conversion | 28K | $4.09 | $114K | 1.4M |
| 2026-03-02 | Hecht Beth | See Remarks | Sell | 100 | $7.06 | $706 | 1.2M |
| 2026-03-02 | Hecht Beth | See Remarks | Sell | 17K | $6.24 | $103K | 1.2M |
| 2026-02-24 | Nguyen Anh Tu | See Remarks | Tax withholding | 29K | $6.88 | $202K | 395K |
| 2026-02-02 | Hecht Beth | See Remarks | Sell | 17K | $7.45 | $124K | 1.2M |
| 2026-01-31 | Shannon John Patrick Jr | See Remarks | Tax withholding | 111K | $7.36 | $815K | 2.9M |
| 2026-01-31 | Shannon John Patrick Jr | See Remarks | Tax withholding | 112K | $7.36 | $822K | 3.0M |
| 2026-01-31 | Shannon John Patrick Jr | See Remarks | Tax withholding | 118K | $7.36 | $869K | 3.2M |
| 2026-01-31 | Pieper Steven | See Remarks | Tax withholding | 27K | $7.36 | $201K | 1.4M |
| 2026-01-31 | Pieper Steven | See Remarks | Tax withholding | 66K | $7.36 | $489K | 1.4M |
| 2026-01-31 | Pieper Steven | See Remarks | Tax withholding | 112K | $7.36 | $823K | 1.5M |
| 2026-01-31 | McCulloch Kevin | See Remarks | Tax withholding | 27K | $7.36 | $201K | 1.7M |
| 2026-01-31 | McCulloch Kevin | See Remarks | Tax withholding | 30K | $7.36 | $223K | 1.8M |
| 2026-01-31 | McCulloch Kevin | See Remarks | Tax withholding | 68K | $7.36 | $504K | 1.8M |
| 2026-01-31 | Hecht Beth | See Remarks | Tax withholding | 24K | $7.36 | $179K | 1.3M |
| 2026-01-31 | Hecht Beth | See Remarks | Tax withholding | 47K | $7.36 | $345K | 1.3M |
| 2026-01-31 | Hecht Beth | See Remarks | Tax withholding | 98K | $7.36 | $724K | 1.3M |
| 2026-01-30 | Shannon John Patrick Jr | See Remarks | Grant | 478K | $0.00 | $0 | 3.3M |
| 2026-01-30 | Pieper Steven | See Remarks | Grant | 155K | $0.00 | $0 | 1.6M |
| 2026-01-30 | Nguyen Anh Tu | See Remarks | Grant | 121K | $0.00 | $0 | 424K |
| 2026-01-30 | McCulloch Kevin | See Remarks | Grant | 168K | $0.00 | $0 | 1.9M |
| 2026-01-30 | Hecht Beth | See Remarks | Grant | 121K | $0.00 | $0 | 1.4M |
| 2026-01-08 | McCulloch Kevin | See Remarks | Sell | 15K | $8.00 | $120K | 1.7M |
| 2026-01-05 | Shannon John Patrick Jr | See Remarks | Exercise or conversion | 3K | $3.94 | $11K | 2.8M |
| 2026-01-05 | Shannon John Patrick Jr | See Remarks | Exercise or conversion | 25K | $1.55 | $39K | 2.8M |
| 2026-01-05 | Shannon John Patrick Jr | See Remarks | Exercise or conversion | 64K | $1.55 | $100K | 2.8M |
| 2026-01-05 | Shannon John Patrick Jr | See Remarks | Sell | 25K | $7.08 | $176K | 2.7M |
| 2026-01-02 | Hecht Beth | See Remarks | Sell | 17K | $7.43 | $124K | 1.3M |
| 2025-12-19 | JOHNSON JOHN | Director | Sell | 135K | $7.22 | $977K | 698K |
| 2025-12-12 | BORMANN-KENNEDY BARBARA-JEAN ANNE | Director | Sell | 15K | $7.09 | $106K | 143K |
| 2025-12-01 | Hecht Beth | See Remarks | Sell | 17K | $7.01 | $117K | 1.3M |
| 2025-11-14 | Shannon John Patrick Jr | See Remarks | Exercise or conversion | 87K | $1.55 | $135K | 2.7M |
| 2025-11-13 | Shannon John Patrick Jr | See Remarks | Sell | 23K | $7.46 | $173K | 2.6M |
| 2025-11-13 | Shannon John Patrick Jr | See Remarks | Exercise or conversion | 9K | $1.55 | $14K | 2.7M |
| 2025-11-11 | Hecht Beth | See Remarks | Sell | 17K | $7.40 | $123K | 1.3M |
| 2025-10-02 | McCulloch Kevin | See Remarks | Tax withholding | 733 | $8.31 | $6K | 1.7M |
| 2025-09-11 | PERSKY MARLA | Director | Sell | 16K | $7.72 | $120K | 142K |
| 2025-09-11 | McCulloch Kevin | See Remarks | Other transaction | 2K | $0.00 | $0 | 0 |
| 2025-08-28 | SHERMAN JEFFREY W | Director | Sell | 42K | $7.92 | $335K | 219K |
| 2025-08-28 | SHERMAN JEFFREY W | Director | Exercise or conversion | 47K | $6.66 | $313K | 261K |
| 2025-08-13 | JOHNSON JOHN | Director | Sell | 108K | $7.32 | $786K | 833K |
| 2025-08-12 | HALKUFF DAWN | Director | Sell | 43K | $7.28 | $309K | 115K |
| 2025-08-01 | Shannon John Patrick Jr | See Remarks | Tax withholding | 37K | $5.38 | $199K | 2.7M |
| 2025-08-01 | McCulloch Kevin | See Remarks | Tax withholding | 15K | $5.38 | $79K | 1.7M |
| 2025-06-13 | McCulloch Kevin | See Remarks | Buy | 25K | $4.38 | $109K | 1.7M |
| 2025-06-04 | Kong Garheng | Director | Grant | 50K | $0.00 | $0 | 214K |
| 2025-06-04 | JOHNSON JOHN | Director | Grant | 50K | $0.00 | $0 | 941K |
| 2025-06-04 | SHERMAN JEFFREY W | Director | Grant | 50K | $0.00 | $0 | 214K |
| 2025-06-04 | HALKUFF DAWN | Director | Grant | 50K | $0.00 | $0 | 158K |
| 2025-06-04 | PERSKY MARLA | Director | Grant | 50K | $0.00 | $0 | 158K |
| 2025-06-04 | BORMANN-KENNEDY BARBARA-JEAN ANNE | Director | Grant | 50K | $0.00 | $0 | 158K |
| 2025-04-02 | McCulloch Kevin | See Remarks | Tax withholding | 733 | $5.15 | $4K | 1.7M |
| 2025-03-28 | Brady James Aloysius | Director | Grant | 100K | $0.00 | $0 | 100K |
| 2025-03-20 | Hecht Beth | See Remarks | Sell | 40K | $5.43 | $217K | 1.4M |
| 2025-01-31 | Shannon John Patrick Jr | See Remarks | Tax withholding | 111K | $3.56 | $394K | 2.0M |
| 2025-01-31 | JOHNSON KENNETH ERLAND | See Remarks | Tax withholding | 15K | $3.56 | $55K | 346K |
| 2025-01-31 | JOHNSON KENNETH ERLAND | See Remarks | Tax withholding | 26K | $3.56 | $92K | 320K |
| 2025-01-31 | Pieper Steven | See Remarks | Grant | 185K | $0.00 | $0 | 1.4M |
| 2025-01-31 | Pieper Steven | See Remarks | Tax withholding | 111K | $3.56 | $394K | 1.3M |
| 2025-01-31 | Pieper Steven | See Remarks | Tax withholding | 66K | $3.56 | $237K | 1.2M |
| 2025-01-31 | Hecht Beth | See Remarks | Tax withholding | 46K | $3.56 | $163K | 1.3M |
| 2025-01-31 | Hecht Beth | See Remarks | Grant | 185K | $0.00 | $0 | 1.4M |
| 2025-01-31 | Hecht Beth | See Remarks | Tax withholding | 98K | $3.56 | $350K | 1.2M |
| 2025-01-31 | Shannon John Patrick Jr | See Remarks | Grant | 800K | $0.00 | $0 | 2.7M |
| 2025-01-31 | Shannon John Patrick Jr | See Remarks | Tax withholding | 111K | $3.56 | $394K | 1.9M |
| 2025-01-31 | McCulloch Kevin | See Remarks | Grant | 185K | $0.00 | $0 | 1.7M |
Form 4 filings are due within two business days of the trade. Insiders sell for many reasons that say nothing about the company; open-market buys are rarer.
Planned sales (Form 144)
Newest first. JSON19 Form 144 notices on file for XERS worth $6.7M at the prices reported; 4 in the last 90 days worth $1.8M. Latest: BETH HECHT filed on 2026-11-02 to sell 75,000 shares ($803K) from 2026-11-02.
| Filed | Seller | Shares | Market value | Of outstanding | Sale from | Broker |
|---|---|---|---|---|---|---|
| 2026-11-02 | BETH HECHTOfficer | 75K | $803K | 0.041% | 2026-11-02 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2026-10-01 | BETH HECHTOfficer | 17K | $159K | 0.009% | 2026-10-01 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2026-09-28 | KEVIN MCCULLOCHOfficer | 70K | $637K | 0.038% | 2026-09-28 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2026-08-12 | STEVEN PIEPEROfficer | 20K | $168K | 0.011% | 2026-08-12 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2026-07-07 | STEVEN PIEPEROfficer | 28K | $231K | 0.016% | 2026-07-07 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2026-07-06 | STEVEN PIEPEROfficer | 17K | $144K | 0.010% | 2026-07-06 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2026-07-01 | KEVIN MCCULLOCHOfficer | 120K | $950K | 0.070% | 2026-07-01 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2026-07-01 | BETH HECHTOfficer | 50K | $396K | 0.029% | 2026-07-01 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2026-06-04 | JOHN H JOHNSONDirector | 15K | $88K | 0.009% | 2026-06-04 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2026-06-04 | DAWN HALKUFFDirector | 20K | $118K | 0.012% | 2026-06-04 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2026-06-04 | Barbara-Jean Bormann-KennedyDirector | 16K | $94K | 0.009% | 2026-06-04 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2026-06-03 | MARLA PERSKYDirector | 16K | $93K | 0.009% | 2026-06-03 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2026-03-30 | JAMES BRADYDirector | 11K | $59K | 0.006% | 2026-03-30 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2026-03-02 | BETH HECHTOfficer | 67K | $408K | 0.040% | 2026-03-02 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2026-01-08 | KEVIN MCCULLOCHOfficer | 60K | $433K | 0.036% | 2026-01-08 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2025-12-19 | JOHN H JOHNSONDirector | 135K | $977K | 0.082% | 2025-12-19 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2025-12-12 | BARBARA-JEAN A BORMANN-KENNEDYDirector | 15K | $105K | 0.009% | 2025-12-12 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2025-11-13 | JOHN SHANNONDirector, Officer | 48K | $365K | 0.029% | 2025-11-13 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2025-11-12 | BETH HECHTOfficer | 67K | $515K | 0.040% | 2025-11-11 | Morgan Stanley Smith Barney LLC Executive Financial Services |
Large holders (13D and 13G)
One row per reporting person with its latest filing, newest first. JSONNo holder on file reports 5% or more of XERS in its latest filing.
| Filed | Form | Holder | Shares | Of class | Event |
|---|---|---|---|---|---|
| 2026-10-30 | 13G/Ano. 1 | Vanguard Capital Managementinvestment adviser | 9.1M | 5.0% | 2026-09-30 |
| 2026-03-27 | 13G/Ano. 2 | The Vanguard Groupinvestment adviser | 0 | 0.0% | 2026-03-13 |
13F holders
Tracked managers holding XERS at their latest 13F. JSON6 of the 30 tracked managers held XERS at their latest 13F, $95.8M in total at quarter-end prices. D. E. Shaw & Co. is the largest at $61.8M (0.0% of its portfolio) as of 2026-06-30. Over the prior quarter 2 added shares and 4 cut.
| Fund | Quarter | Shares | Value | Of portfolio | Change in shares |
|---|---|---|---|---|---|
| D. E. Shaw & Co. | 2026-06-30 | 7.8M | $61.8M | 0.03% | +16K |
| Two Sigma Investments | 2026-06-30 | 1.9M | $14.9M | 0.01% | -39K |
| AQR Capital Management | 2026-06-30 | 1.5M | $12.2M | 0.00% | +147K |
| Citadel Advisors | 2026-06-30 | 665K | $5.3M | 0.00% | -17K |
| Millennium Management | 2026-06-30 | 132K | $1.0M | 0.00% | -2.1M |
| Renaissance Technologies | 2026-06-30 | 67K | $533K | 0.00% | -386K |
Only the 30 tracked managers on the funds hub; a 13F reports long positions in US listed stock at quarter end, 45 days late, and says nothing about shorts or positions sold since.
Financials
SEC XBRL, as filed. JSONIn Q2 FY 2026 (quarter ended 2026-06-30) Xeris Biopharma Holdings reported revenue of $92.1M, up 28.7% from the same quarter a year earlier, and net loss of $31.1M (-0.18 diluted EPS). In FY 2025 it generated $28.6M of operating cash flow. As of 2026-06-30, cash was $121.7M against $252.6M of debt.
- Cash
- $121.7M
- Debt
- $252.6M
- Equity
- -$9.7M
- Total assets
- $411.9M
- Shares outstanding
- 182,320,306
Quarterly, last 8 quarters
| Quarter | Period end | Revenue | Net income | Margin | Diluted EPS |
|---|---|---|---|---|---|
| Q2 FY 2026 | 2026-06-30 | $92.1M | -$31.1M | -33.8% | -0.18 |
| Q1 FY 2026 | 2026-03-31 | $83.1M | $2.2M | 2.7% | 0.01 |
| Q4 FY 2025derived | 2025-12-31 | $85.8M | n/a | n/a | n/a |
| Q3 FY 2025 | 2025-09-30 | $74.4M | $621K | 0.8% | 0.00 |
| Q2 FY 2025 | 2025-06-30 | $71.5M | -$1.9M | -2.7% | -0.01 |
| Q1 FY 2025 | 2025-03-31 | $60.1M | -$9.2M | -15.3% | -0.06 |
| Q4 FY 2024derived | 2024-12-31 | $60.1M | n/a | n/a | n/a |
| Q3 FY 2024 | 2024-09-30 | $54.3M | -$15.7M | -29.0% | -0.11 |
Fiscal years, with buybacks and dividends
| Fiscal year | Ends | Revenue | Net income | Operating cash flow | Capex | Buybacks | Dividends |
|---|---|---|---|---|---|---|---|
| FY 2025 | 2025-12-31 | $291.8M | $554K | $28.6M | n/a | n/a | n/a |
| FY 2024 | 2024-12-31 | $203.1M | -$54.8M | -$37.0M | n/a | n/a | n/a |
| FY 2023 | 2023-12-31 | $163.9M | -$62.3M | -$47.0M | n/a | n/a | n/a |
| FY 2022 | 2022-12-31 | $110.2M | -$94.7M | -$102.9M | n/a | n/a | n/a |
| FY 2021 | 2021-12-31 | $49.6M | -$122.7M | -$95.5M | $1.1M | n/a | n/a |
Quarters are the three-month figures the company reports; a fourth quarter marked derived is the fiscal year less the three reported quarters, since companies report it only inside the 10-K. Fiscal years are the annual figures. Buybacks are the cash the company paid to repurchase its common stock in the year, not the amount authorized. Balance sheet lines are as of 2026-06-30; shares outstanding as of 2026-07-31 from the cover page.
What this page is
Xeris Biopharma Holdings in the regulatory record
Regulators publish company data in separate files that never sit next to each other: FINRA's twice-monthly short interest, its daily short sale volume, the SEC's fails-to-deliver counts, and each insider's Form 4. A company page puts those series for one ticker on one URL, with planned sales, large holders, 13F holders and financials beside them, so the short position, the daily flow, the settlement fails and what insiders are doing can be read together.
Each section has its own history table, a one-line summary of the latest figures and its own JSON and CSV links, and says when its source last updated.
This page follows Xeris Biopharma Holdings (XERS), SEC CIK 1867096, listed on Nasdaq, classified by the SEC as pharmaceutical preparations. The cross-market tables live on the short interest and insider transactions hubs.
Source and updates
- Short interest
- FINRA consolidated short interestSource: FINRA.Twice a month, about eight business days after settlement. Latest 2026-10-15.JSON and CSV
- Daily short volume
- FINRA Reg SHO daily filesSource: FINRA.Every trading day, the morning after FINRA posts it. Latest 2026-11-02.JSON and CSV
- Fails to deliver
- SEC fails-to-deliver dataSource: SEC.Twice a month, a few weeks after the half month ends. Latest 2026-09-30.JSON and CSV
- Planned sales
- SEC EDGAR Form 144Source: SEC.New notices appear shortly after the SEC posts them; a notice is filed on or before the sale. Latest 2026-11-02.JSON and CSV
- Large holders
- SEC EDGAR Schedule 13D and 13GSource: SEC.New filings appear shortly after the SEC posts them. A 13D is due within five business days of crossing 5%; a 13G follows the passive schedule. Latest 2026-10-30.JSON and CSV
- 13F holders
- SEC EDGAR Form 13F-HRSource: SEC.Quarterly, filed within 45 days of quarter end; 30 tracked managers. Latest 2026-06-30.JSON and CSV
- Financials
- SEC EDGAR 10-K and 10-Q filingsSource: SEC.Weekly; values are as filed in the 10-Q and 10-K. Latest 2026-06-30.JSON and CSV
- Earnings dates
- SEC EDGAR 8-K filings (Item 2.02)Source: SEC.Twice a day. Reported dates come from the company's 8-K filings; the next date is marked as an estimate until the 8-K arrives. Latest 2026-08-06.JSON and CSV
- Insider trades
- SEC EDGAR Form 4Source: SEC.New filings appear shortly after the SEC posts them; they're due two business days after the trade. Latest 2026-10-01.JSON and CSV
- Company record
- EDGAR filing index for CIK 1867096Ticker, name and exchange from the SEC's company list, refreshed weekly.
- Rate limits
- 10 requests a minute without a key, 30 with a free key from a free account.
How to read it
- Read the position against the flow: rising short interest with a high daily short share is new shorting; rising short interest with a normal short share is old shorts holding on.
- Insider buys next to a large short position are rare and stand out; insider sells next to one are common and mean little.
- Fails to deliver matter relative to the float, not in absolute shares; a million failed shares in a mega cap is noise.
Analysis of what the data shows, not advice. XOOMAR does not recommend buying, selling or holding anything.
Other companies the SEC classifies as pharmaceutical preparations
Other company pages
- STESTERIS
- STLDSteel Dynamics
- STRCStrategy
- STRLSterling Infrastructure
- STTState Street
- STXSeagate Technology Holdings
- STZConstellation Brands
- SUISun Communities
- SUNBSunbelt Rentals Holdings
- SWSmurfit Westrock
- SWKStanley Black & Decker
- SWKSSkyworks Solutions
- SXTCChina SXT Pharmaceuticals
- SYFSynchrony Financial
- SYKStryker
- SYNASynaptics
Datasets
Frequently Asked Questions
How much of XERS is sold short?
8,027,654 shares were held short at the 2026-10-15 settlement, 3.3 days of average volume. FINRA publishes the next count about eight business days after the 15th and the last business day of the month.
What is XERS's daily short volume?
On 2026-11-02, 257,156 of the 838,331 XERS shares reported to FINRA were sold short, 30.7% of the day's reported volume. Short volume is a flow for one day, not a position.
Does XERS have fails to deliver?
The SEC's latest file shows 209,157 XERS shares failed to deliver at settlement 2026-09-30. Fails are reported per settlement date and published twice a month with a lag.
Are XERS insiders buying or selling?
Insiders at XERS reported 8 open-market sells worth $949K in the last 90 days and no open-market buys. Latest filing: McCulloch Kevin (See Remarks) on 2026-10-01.
Have XERS insiders filed to sell?
19 Form 144 notices on file for XERS worth $6.7M at the prices reported; 4 in the last 90 days worth $1.8M. Latest: BETH HECHT filed on 2026-11-02 to sell 75,000 shares ($803K) from 2026-11-02.
Who owns 5% or more of XERS?
No holder on file reports 5% or more of XERS in its latest filing.
What did XERS report last quarter?
In Q2 FY 2026 (quarter ended 2026-06-30) Xeris Biopharma Holdings reported revenue of $92.1M, up 28.7% from the same quarter a year earlier, and net loss of $31.1M (-0.18 diluted EPS). In FY 2025 it generated $28.6M of operating cash flow. As of 2026-06-30, cash was $121.7M against $252.6M of debt.
Which tracked 13F managers own XERS?
6 of the 30 tracked 13F managers held XERS shares at their latest filing, $95.8M in all. The largest: D. E. Shaw & Co. (7.8M shares, $61.8M), Two Sigma Investments (1.9M shares, $14.9M), Cliff Asness's AQR Capital Management (1.5M shares, $12.2M), Ken Griffin's Citadel Advisors (665K shares, $5.3M), Izzy Englander's Millennium Management (132K shares, $1.0M), Renaissance Technologies (67K shares, $533K).
Data on this page is provided for informational purposes only and is not financial advice. See our editorial policy.